Albert David Limited is a pharmaceutical company engaged in the manufacture and marketing of formulations, infusion products, and pharmaceutical preparations. Its portfolio includes products across therapeutic areas such as gynecology, gastroenterology, anti-infectives, and other healthcare segments. The company also manufactures intravenous fluids and other specialized pharmaceutical products. Growing healthcare expenditure and increasing demand for medicines provide a long-term market opportunity. Product development, regulatory compliance, manufacturing efficiency, pricing, and competition remain important business factors.
| Market cap | Sales (TTM) | Net profit (TTM) | P/E | EPS (TTM) | P/B | ROE | ROE previous year | ROCE | Debt / equity | Free cash flow | EV / EBITDA | Beta |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ₹448 cr | ₹364 cr | ₹23 cr | 19.8 | 39.53 | 1.14 | -0.4% | 4.4% | 0.8% | 0.07 | ₹-7 cr | 36.1 | 0.70 |
| Quarter | Sales ₹ cr | Net profit ₹ cr | EPS | EPS YoY | Sales YoY | Net margin |
|---|---|---|---|---|---|---|
| Jun 2026 | 101 | 32 | 56.07 | +303.1% | +43.6% | 31.6% |
| Mar 2026 | 86 | -21 | -37.56 | — | +14.6% | -25.0% |
| Dec 2025 | 90 | 15 | 26.81 | turnaround | +8.2% | 17.0% |
| Sep 2025 | 87 | -3 | -5.79 | -118.3% | -11.4% | -3.8% |
| Jun 2025 | 71 | 8 | 13.91 | -57.9% | -21.0% | 11.2% |
| Mar 2025 | 75 | -10 | -18.10 | -180.0% | -15.9% | -13.8% |
| Dec 2024 | 83 | -9 | -16.45 | -150.2% | -5.9% | -11.3% |
| Sep 2024 | 98 | 18 | 31.67 | -11.0% | +5.6% | 18.4% |
| Check | Result |
|---|---|
| Latest quarter EPS up 25%+ on a year ago | ✓ Pass |
| EPS growth accelerating over 3 quarters | — Not assessable |
| Sales up 25%+, or sales growth accelerating | ✓ Pass |
| Annual EPS up 25%+ in each of the last 2 years | — Not assessable |
| Net margin above the same quarter last year | ✓ Pass |
| Method | Checks | Score | Verdict |
|---|---|---|---|
| Minervini | ✓ Close above the 150- and 200-day averages ✓ 150-day above 200-day ✓ 200-day rising for a month ✓ 50-day above the 150- and 200-day ✗ Close above the 50-day ✓ At least 25% above the 52-week low · low 587.05 ✓ Within 25% of the 52-week high · high 898.60 ✓ RS percentile 70 or more · RS 73 Minervini's trend template - the gate the scanner applies. | 7/8 | 7 of 8 |
| Weinstein | Stan Weinstein's stage analysis on the 30-week moving average. | Stage 2 - advancing | |
| CAN SLIM | ✓ C latest quarter EPS up 25%+ — A annual EPS up 25%+ in each of the last 2 years · O'Neil asks 3; ~2 held ✓ N within 15% of the 52-week high · high 898.60 ✓ S more volume on up days than down days (50 sessions) · 1.54x ✗ L RS percentile 80 or more · RS 73 — I institutional sponsorship rising (FII + DII) · not yet collected for this stock ✗ M market in an uptrend (40%+ of stocks above their 200-day) · breadth 37% William O'Neil's growth-leader checklist. | 3/5 | Average |
| Darvas | ✓ Box top confirmed (3 sessions below the new high) · top 931.85 ✗ Box bottom confirmed (3 sessions holding) · bottom 765.00 ✗ Close above the box top · close 784.30 ✗ Volume at least 1.5x its 50-day average · 0.5x Nicolas Darvas's box: a breakout above a confirmed box after a new high. | 49/100 | In box |
| Turtle | ✗ Close above the prior 55-session high · 931.85 ✗ Close above the prior 20-session high · 898.00 ✗ Close below the prior 20-session low · 765.00 Donchian channel breakout - the Turtle traders' entry. | No signal | |
| Greenblatt | — Earnings yield (EBITDA / EV) · 2.8% — Return on capital (ROCE) · 0.8% Joel Greenblatt's Magic Formula: good businesses at good prices, ranked across all companies. Earnings yield uses EBITDA, as EBIT is not held separately. | 3/100 | Weak |
| Graham | ✗ Price at or below the Graham number · Graham number 782.25 ✗ P/E 15 or less · P/E 19.8 ✓ P/B 1.5 or less (or P/E x P/B 22.5 or less) · P/B 1.14 ✓ Current ratio 2 or more · 3.24 — 10 years of positive earnings, 20 of dividends · history not held Benjamin Graham's defensive-investor tests. | 100/100 | Fair |
| Piotroski | ✗ Profitable (ROA > 0) ✗ Operating cash flow positive ✗ ROA rising ✗ Cash flow above net profit (earnings quality) ✓ Long-term debt / assets falling ✗ Current ratio rising · 3.24 ✓ No new shares issued ✗ Margin rising (net margin) ✗ Asset turnover rising Joseph Piotroski's F-score, FY 2025 -> 2026. | 2/9 | Weak |
| Stock | 1M % | 3M % | 6M % | 1Y % | 3Y % | 5Y % | P/E | P/B | ROE % | ROCE % | ROA % | D/E | EV/EBITDA | ₹ Cr | Sales TTM ₹ Cr | Profit TTM ₹ Cr | EPS | Beta |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ALBERTDAVD this stock | -7.6 | +14.7 | +9.5 | -1.7 | -7.8 | +33.9 | 19.8 | 1.14 | -0.4 | 0.8 | -0.29 | 0.07 | 36.1 | 448 | 364 | 23 | 39.5 | 0.70 |
| SCPL | -10.2 | +1.5 | +86.3 | +156.2 | +33.8 | — | 29.9 | 3.96 | 13.2 | — | — | 0.32 | 15.6 | 622 | 386 | 21 | 19.8 | 0.50 |
| NOVARTIND | -14.6 | +0.7 | +70.9 | +150.6 | +139.8 | +121.9 | 42.5 | 5.08 | 12.0 | — | — | — | — | 4,156 | — | — | 39.6 | — |
| PREMIERPOL | +14.5 | +17.9 | +69.8 | +110.6 | +235.8 | +576.9 | 26.3 | 5.85 | 24.1 | 32.9 | 17.42 | 0.00 | 21.3 | 982 | 396 | 37 | 3.5 | 0.64 |
| CALSOFT | -27.0 | +35.9 | +136.9 | +63.2 | +107.3 | -14.3 | 12.2 | 4.33 | 32.3 | 42.0 | 27.61 | 0.04 | — | — | 25 | 15 | 2.4 | 0.62 |
| VALIANTLAB | +5.2 | +113.0 | +98.1 | +61.3 | -29.3 | — | 45.3 | 2.34 | -1.2 | 0.8 | -0.76 | 0.14 | 88.1 | 726 | 306 | 16 | 3.0 | 0.81 |
| AKSHARCHEM | -4.0 | +67.7 | +92.9 | +50.9 | +42.7 | -23.1 | 22.5 | 1.21 | -0.2 | 0.7 | -0.10 | 0.41 | 22.5 | 316 | 416 | 14 | 17.5 | 0.81 |
| KENNAMET | -16.7 | +31.5 | +48.1 | +47.3 | +43.2 | +163.5 | 40.9 | 9.39 | 23.0 | — | — | — | — | 8,017 | — | — | 89.2 | — |
| CHEMBONDCH | -10.8 | -9.5 | +53.2 | +44.3 | — | — | 16.5 | 3.03 | 18.5 | — | — | 0.00 | 12.0 | 627 | 347 | 38 | 14.2 | 1.27 |
| MARALOVER | +3.6 | +7.2 | +31.5 | +29.6 | -15.9 | -23.3 | — | 2.21 | — | — | — | — | — | — | — | — | — | 1.02 |
| IVP | -12.6 | +30.5 | +37.8 | +25.3 | +18.1 | +75.4 | 6.6 | 1.33 | 12.6 | 13.9 | 5.42 | 0.42 | 7.0 | 208 | 611 | 32 | 30.5 | 1.05 |
← All NSE stocks · More Other stocks